Published in Medical Letter on the CDC and FDA, December 19th, 2004
Biovail's NDA submission, which was accepted for review by the FDA in late February 2004, included clinical and safety data obtained from four original adequate and well-controlled trials involving more than 3000 patients who received doses of up to 400mg of Ralivia ER once daily.
The submission also included 12 definitive and five supportive pharmacokinetic studies which...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA